BACKGROUND AND AIM: We investigated the prognosis of patients with C-viral chronic liver disease (C-CLD) according to the efficacy of interferon (IFN) therapy in a long-term retrospective cohort study. METHODS: Of 721 patients with C-CLD who underwent liver biopsy between January 1986 and December 2005, 577 were treated with IFN, and 221 of these patients achieved sustained virological response (SVR) with a follow-up period of 9.9 ± 5.3 years. RESULTS: The annual rate of HCC development was 2.71%/year, 2.31%/year, and 0.24%/year in untreated, non-SVR, and SVR patients, respectively. Multivariate Cox proportional regression analysis showed that the risk of HCC development was significantly lower in SVR patients than in untreated or non-SVR patients; moreover, this risk was similar in non-SVR patients and untreated patients. The annual mortality rate in overall death was 3.19%/year, 1.98%/year, and 0.44%/year in untreated, non-SVR, and SVR patients, respectively. Multivariate Cox proportional hazards regression analysis showed that the SVR status reduced the risk ratio for overall death to 0.173, whereas the non-SVR status did not significantly reduce the risk ratio. CONCLUSIONS: The risk ratio of overall death and HCC development was significantly reduced in SVR patients, whereas no significant reduction was found in non-SVR patients in a long-term cohort study.
BACKGROUND AND AIM: We investigated the prognosis of patients with C-viral chronic liver disease (C-CLD) according to the efficacy of interferon (IFN) therapy in a long-term retrospective cohort study. METHODS: Of 721 patients with C-CLD who underwent liver biopsy between January 1986 and December 2005, 577 were treated with IFN, and 221 of these patients achieved sustained virological response (SVR) with a follow-up period of 9.9 ± 5.3 years. RESULTS: The annual rate of HCC development was 2.71%/year, 2.31%/year, and 0.24%/year in untreated, non-SVR, and SVR patients, respectively. Multivariate Cox proportional regression analysis showed that the risk of HCC development was significantly lower in SVR patients than in untreated or non-SVR patients; moreover, this risk was similar in non-SVR patients and untreated patients. The annual mortality rate in overall death was 3.19%/year, 1.98%/year, and 0.44%/year in untreated, non-SVR, and SVR patients, respectively. Multivariate Cox proportional hazards regression analysis showed that the SVR status reduced the risk ratio for overall death to 0.173, whereas the non-SVR status did not significantly reduce the risk ratio. CONCLUSIONS: The risk ratio of overall death and HCC development was significantly reduced in SVR patients, whereas no significant reduction was found in non-SVR patients in a long-term cohort study.
Authors: Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2014-09-19 Impact factor: 3.199
Authors: José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero Journal: PLoS One Date: 2012-05-29 Impact factor: 3.240
Authors: Francesca Romana Ponziani; Francesca Mangiola; Cecilia Binda; Maria Assunta Zocco; Massimo Siciliano; Antonio Grieco; Gian Lodovico Rapaccini; Maurizio Pompili; Antonio Gasbarrini Journal: World J Hepatol Date: 2017-03-08
Authors: Kurinchi S Gurusamy; Edward Wilson; Ronald L Koretz; Victoria B Allen; Brian R Davidson; Andrew K Burroughs; Christian Gluud Journal: PLoS One Date: 2013-12-12 Impact factor: 3.240